Getting your Trinity Audio player ready... Boulder’s Array BioPharma Inc. is merging with Pfizer Inc. in an $11.4 billion deal. The merger agreement was announced Monday. Array BioPharma is a ...

NEW YORK, and BOULDER, Colo., June 17, 2019 /PRNewswire/ -- Pfizer Inc (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement ...

What: Shares of Array BioPharma, a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from ...

Pfizer, Inc. PFE announced a definitive agreement to buy small cancer drugmaker, Array BioPharma Inc. ARRY for $48 per share in cash for a total enterprise value of approximately $11.4 billion. Pfizer ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Positive clinical trial results gave investors a reason to cheer. The Beacon trial enrolled 615 patients with BRAF-mutant colorectal cancer who have relapsed at least once. Patients receiving Array's ...

NEW YORK (AP) — Pfizer is buying the cancer treatment company Array BioPharma in a deal worth $11.4 billion. Array has a combination therapy for BRAF-mutant metastatic melanoma, along with a pipeline ...

Array BioPharma Inc. of Boulder, Colo., and Celgene Corporation, a Summit-based biopharmaceutical company, have announced a research and development collaboration on the discovery, development and ...

Boulder pharmaceutical firm Array BioPharma, Inc. posted losses of more than $147.3 million for the full 2018 fiscal year, which ended June 30. That loss is up from $116.8 million in 2017. The company ...

Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to ...